{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-065567","form_type":"8-K","ticker":"CADL","cik":"0001841387","company_name":"Candel Therapeutics, Inc.","filed_at":"2023-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.957364+00:00","generated_at":"2026-06-07T22:51:01.884728+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Candel Therapeutics receives Nasdaq delisting notice for bid price below $1.00","bullets":["Nasdaq notified CADL that bid price below $1.00 for 30 consecutive business days.","Company has 180 days, until May 13, 2024, to regain compliance.","Compliance requires closing bid price at $1.00 or more for 10 consecutive business days.","If not compliant, may qualify for second 180-day period by transferring to Nasdaq Capital Market.","Common stock continues trading on Nasdaq Global Market under CADL; no immediate effect."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-065567","json":"https://secwatch.observer/filing/0000950170-23-065567.json","markdown":"https://secwatch.observer/filing/0000950170-23-065567.md","text":"https://secwatch.observer/filing/0000950170-23-065567.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841387/000095017023065567/0000950170-23-065567-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841387/000095017023065567/cadl-20231115.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T22:51:01.884728+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5a56d37fd20ba0384927856262ea152b034a77c4","claim":"Candel Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).","evidence_excerpt":"November 15, 2023, Candel Therapeutics, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the previous 30 consecutive business days, the closing bid price for the Company’s common stock, par value $0.01 per share (the “Common Stock”), had been below the minimum $1.00 per share required for continued listing on The Nasdaq Global Market under Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). The Notice has no effect at this time on the Common Stock, w","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1841387/000095017023065567/0000950170-23-065567-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5450(a)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}